Medical
-
Pulmatrix announced that it will halt a Phase 2b trial of PUR1900 dry powder itraconazole (Pulmazole) in patients with allergic bronchopulmonary aspergillosis (ABPA) that was initiated in February 2023. The company says that the move is part… Read more . . .
-
Liquidia Corporation announced that it has initiated the ASCENT open-label safety and tolerability study of Yutrepia (LIQ861) treprostinil DPI in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The 52-week study is expected… Read more . . .
-
Theravance Biopharma announced that the Phase 4 PIFR-2 study of nebulized Yupelri revefenacin inhalation solution versus Spiriva HandiHaler tiotropium DPI in patients with severe to very severe COPD failed to demonstrate any significant difference in… Read more . . .
-
Italian start-up NanoPhoria has announced the publication of an article titled “Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure” in the Journal of the American College of Cardiology (JACC).… Read more . . .
-
Tiziana Life Sciences announced the initiation of a Phase 2a study of intranasal foralumab in patients with non-active secondary-progressive multiple sclerosis (na-SPMS), with a primary endpoint of change in microglial activation as determined by PET… Read more . . .
-
Vivaldi Biosciences announced that the Flu Lab has provided a grant to fund a transmission study of the company’s DeltaFLU intranasal universal influenza vaccine. According to the company, the study will evaluate the ability of… Read more . . .
-
After recently receiving authorization for a Phase 1 trial of its ETH47 mRNA therapy, Ethris has initiated the study, the company announced. The trial is expected to enroll 88 healthy participants aged 18 to 55… Read more . . .
-
Agomab Therapeutics announced that it has initiated a Phase 1 trial of its AGMB-447 inhaled ALK5 inhibitor that is expected to enroll 76 healthy subjects and idiopathic pulmonary fibrosis (IPF) patients. According to Agomab, the… Read more . . .
-
Nasus Pharma said that in a second PK study of FMXIN002 intranasal dry powder epinephrine, 91% of subjects who received a 4 mg dose of the nasal formulation reached the clinical threshold for plasma exposure… Read more . . .
-
Acadia Pharmaceuticals said that it has initiated the Phase 3 COMPASS PWS study of ACP-101 carbetocin nasal spray for the treatment of excessive hunger in people with Prader-Willi syndrome (PWS). Acadia acquired the carbetocin nasal… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland